Lv1
10 积分 2023-09-24 加入
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
6天前
已完结
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
6天前
已完结
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
6天前
已关闭
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
3个月前
已完结
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
3个月前
已完结
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
3个月前
已完结
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
3个月前
已完结
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
3个月前
已关闭
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
3个月前
已完结
EGFR-mutated NSCLC: A roadmap to treatment sequences
3个月前
已完结
皖公网安备34019202002308
